Clinical outcomes of doxorubicin-eluting CalliSpheres® beads-transarterial chemoembolization for unresectable or recurrent esophageal carcinoma

Abstract

Background The clinical outcomes of drug-eluting beads transarterial chemoembolization (DEB-TACE) with doxorubicin-loaded CalliSpheres® beads for patients with unresectable or recurrent esophageal carcinoma have not been reported. The aim of this study is to study the clinical outcomes of DEB-TACE for patients with unresectable or recurrent esophageal carcinoma. Methods This retrospective study enrolled 21 patients (15 men; mean age 68.7 ± 9.7; range 46–86 years) with unresectable or recurrent esophageal carcinoma received DEB-TACE between July 2017 and September 2020. Patient characteristic data, imaging findings, complications and DEB-TACE procedure were reviewed. The primary endpoints, disease control rate (DCR) and objective response rate (ORR), were calculated. The secondary endpoints were overall survival rate and progression-free survival (PFS). Results Twenty-two sessions of DEB-TACE were performed in 21 patients. The technical success rate was 100%; without sever adverse events or procedure-related deaths. All patients received transarterial chemotherapy infusion with raltitrexed or oxaliplatin. The median follow-up period was 3.6 months (interquartile range, IQR 1.5–9.4 months). ORR and DCR were 42.9 and 85.7%, 28.6 and 71.4%, 20.0 and 40.0% respectively at 1-, 3-, and 6-months after DEB-TACE. The median PFS was 6.0 months, and the 3-, 6- and 12-month PFS rates were 68.2%, 45.5 and 0.0%, respectively. The median overall survival was 9.4 months, and the 3-, 6- and 12-month overall survival rates were 75.5%, 55.0 and 13.8%, respectively. Conclusions To our knowledge, this is the first study reports outcomes of DEB-TACE with doxorubicin-loaded CallSpheres bead treatment in the management of patients with unresectable or recurrent esophageal carcinoma. According to our results, this is a safe and feasible treatment modality that may be considered among the options for the treatment of these patients.

Preliminary outcomes of raltitrexed eluting bead-transarterial chemoembolization using Callispheres® beads for gastrointestinal adenocarcinoma liver metastasis

“…DEB-TACE, as an alternative choice for unresectable cancer, shows an advantage of increased local chemotherapy concentration and sustained release of antitumor drugs [14][15][16][17]. CB is the first polyvinyl alcohol microsphere product developed in China, which can load several kinds of chemotherapeutic drugs, including irinotecan.…”

“…Transarterial chemoembolization (TACE) and drugeluting bead TACE (DEB-TACE) are alternative treatments for chemotherapy refractory patients with GALM [12,13]. As a novel drug-delivering device, DEB-TACE showed a advantage of increased local chemotherapy concentration and sustained release of anti-tumor drugs [14][15][16][17]. Previous studies have indicated that DEB-TACE with Callispheres ® beads (CB) is safe and effective in many types of malignant tumors [18][19][20].…”

Transarterial chemoembolization of unresectable renal cell carcinoma with doxorubicin-loaded CalliSpheres drug-eluting beads

“…Currently, DEB-TACE has been widely used in the treatment of unresectable carcinoma of substantial organs (e.g. liver 6 , 7 , uterus 8 or lung 9 ) rather than cavity organs such as bladder and digestive tract 3 , 15 . Our results indicated that DEB-TACE using doxorubicin-loaded CB is feasible, safe and showed good short-term efficacy without serious adverse events.…”

Transcatheter arterial chemoembolization is safe and effective for patients with late-stage or recurrent oral carcinoma

“…Currently, TACE has been emerging as a palliative treatment for many kinds of late-stage carcinomas. By using local infusion of chemotherapeutic drugs at high dosage and embolization of tumor-feeding arteries for nutritional deprivation, TACE can cause tumor to shrink, necrosis, or even disappear (14)(15)(16). Besides, preoperative TACE may be beneficial to distinguish tumor boundaries from normal surrounding tissue and improve the resection rate by decreasing tumor volume and intraoperative bleeding (10), when compared with traditional treatments (17,18).…”